Group 1 - The beauty blogger "Dr. Big Mouth" (Hao Yu) raised questions about the testing results released by Giant Bio, specifically regarding the choice of testing methods and the accuracy of the results [1] - Concerns were expressed about the discrepancy between the claimed 100% homology of recombinant collagen with human collagen and the actual 86% homology based on Giant Bio's own patent [1] - The blogger highlighted the lack of a blank control in the biuret test, which is crucial for accurately measuring the presence of recombinant collagen in the formulation [1] Group 2 - Recently, the international testing company SGS declined a testing request from the blogger's team, citing the controversial nature of the tests and a desire to avoid involvement [2] - The blogger criticized SGS for its decision to return the testing request, arguing that testing institutions should uphold social responsibility beyond profit motives [2] - In response to Giant Bio's statement about the availability of its products, the blogger encouraged legal entities to collect samples for future consumer protection efforts [2]

Core Viewpoint - The latest developments in the competition between Juzi Bio and Huaxi have emerged, focusing on the testing results of their collagen products and addressing concerns regarding product integrity and consumer misinformation [1]. Group 1: Testing Results - Juzi Bio announced the testing results for its products, confirming the presence of recombinant collagen in both the Human-like Recombinant Collagen Essence (Kefumei Collagen Stick 1.0) and the Recombinant Collagen Essence Liquid (Kefumei Collagen Stick 2.0) [2][3]. - For the Kefumei Collagen Stick 1.0, tests conducted at multiple institutions showed that the recombinant collagen content was greater than 0.1% [2]. - The company utilized LC-MS/MS for qualitative analysis and confirmed that the sodium polyglutamate used in the products did not interfere with the detection results [2][6]. Group 2: Product Integrity and Market Position - Juzi Bio emphasized that its products genuinely contain recombinant collagen and refuted claims of false advertising or misleading consumers [5]. - The Kefumei Collagen Stick 2.0 was launched on April 16, and the 1.0 version is being phased out due to stock depletion, countering rumors of a stealthy withdrawal from the market [5]. - The names of the testing institutions were not disclosed in the public report, with the company indicating that they are referenced as letters (A, B, C, D) for confidentiality [6].

Core Insights - The article discusses the rise of a family business empire valued at over 80 billion, founded by a couple who transitioned from academia to entrepreneurship, highlighting their journey and strategies in the collagen industry [1] Group 1: Company Background - Fan Daidi, born in 1966, became China's first female PhD in biochemical engineering and returned to Northwest University to lead research in human-derived collagen after visiting MIT in 2000 [2] - In 2000, her husband, Yan Jianya, left his stable job to start a business, establishing Xi'an Juzhi Biological Gene Technology Co., Ltd. in an 18-square-meter office, marking the beginning of their family business empire [2] Group 2: Business Development - The turning point for Juzhi Biological came in 2009 with the launch of their first commercial brand, Keli Jin, and the establishment of Xi'an Chuangke Village, which became a major distributor for the company [3] - The company adopted a tiered agency model, allowing individuals to become distributors for a fee, which significantly increased their customer base and sales [3] - From 2019 to 2021, Xi'an Chuangke Village contributed 52.2%, 49.3%, and 29.3% to Juzhi Biological's revenue, respectively, before the company shifted focus to online sales [3][4] Group 3: Revenue Growth and Market Position - By 2021, online direct sales accounted for 41.5% of total revenue, showcasing a significant shift in sales strategy [5] - On November 11, 2021, Juzhi Biological's brand Kefu Mei achieved over 100 million in sales within 13 minutes, marking a peak moment for the company [6] - The company's revenue grew from 957 million in 2019 to 5.538 billion in 2024, with a compound annual growth rate of 42% and a gross margin of 87.2% [6] Group 4: IPO and Leadership Transition - In 2022, the company went public in Hong Kong, becoming the first listed company in the collagen restructuring sector [7] - In 2023, Fan Daidi stepped down as executive director, passing the leadership to their daughter, Yan Yubo, raising questions about the next generation's ability to lead [8] Group 5: Challenges and Controversies - The company faces challenges such as high marketing costs, dependency on a single brand (Kefu Mei), and controversies regarding product integrity and compliance with industry standards [8] - From 2022 to 2024, Kefu Mei accounted for 68.2%, 79.1%, and 87.04% of total revenue, indicating a heavy reliance on this brand [8] - Reports of banned substances in Kefu Mei and allegations of product authenticity have emerged, highlighting the need for clearer industry standards [8][9]

Core Viewpoint - The ongoing dispute between Hyaluronic Acid and recombinant collagen has gained significant attention, particularly involving major players in the medical aesthetics industry, Huaxi Biological and Juzhi Biological, leading to market volatility and investor caution [1][8]. Company Responses - Huaxi Biological expressed support for Dr. Hao Yu, emphasizing the importance of consumer rights and the integrity of product testing, while also indicating that they have conducted thorough evaluations of the claims made by Dr. Hao [2][5]. - Juzhi Biological issued a statement condemning Huaxi Biological's accusations as malicious and unfounded, highlighting their commitment to consumer trust and the integrity of their products [2][3]. Market Reaction - Following the controversy, Juzhi Biological's stock price fell over 5.6% on June 2, closing at 68.25 HKD per share, with a market capitalization of 731 billion HKD, reflecting investor concerns about the ongoing dispute [1][8]. Testing and Standards - The testing report that Dr. Hao Yu referenced was clarified by the testing agency, stating it was not legally valid for public proof and lacked comprehensive methodology, which raised questions about the reliability of the results [3][7]. - The lack of unified testing standards in the recombinant collagen industry has been highlighted as a significant issue, contributing to consumer distrust and regulatory challenges [7][9]. Industry Implications - The incident has exposed vulnerabilities in the regulatory framework and testing standards for the recombinant collagen sector, prompting discussions about the need for clearer guidelines and industry standards [7][9]. - The National Medical Products Administration has initiated the development of industry standards for recombinant collagen testing, indicating a move towards greater regulatory oversight [7].

Group 1 - The Ministry of Defense of China strongly opposes negative remarks made by the U.S. Secretary of Defense regarding China, asserting that such actions will ultimately backfire on the U.S. [5] Group 2 - The sales revenue from the consumer goods trade-in program in China has surpassed 1 trillion yuan this year, indicating a strong recovery in consumer spending. [6] - The program has led to approximately 1.1 trillion yuan in sales across five major categories, with 175 million subsidies issued to consumers. [6] - Specific figures include 4.12 million applications for automobile trade-ins, 49.86 million consumers purchasing 12 categories of home appliances totaling 77.62 million units, and 5.35 million consumers buying 5.66 million digital products. [6] Group 3 - The film box office for the 2025 Dragon Boat Festival period has exceeded 300 million yuan, significantly surpassing last year's figures. [8] Group 4 - NIO confirmed that there has been no change in the shareholding of its president, Qin Lihong, countering false information circulating on various platforms. [17] Group 5 - JD.com plans to expand its full-time delivery rider workforce to 150,000, having already surpassed 100,000 riders ahead of schedule. [19] Group 6 - BYD led the electric vehicle market in May with sales of 382,500 units, a year-on-year increase from 331,800 units. [20] - Other notable performances include Geely's sales of 235,200 units, a 46% increase year-on-year, and significant growth from new entrants like Leap Motor and Xpeng Motors. [20] Group 7 - Hongxin Securities has officially changed its name to Tianfu Securities, signaling a strategic repositioning following the acquisition by Shudao Group. [21]

Core Viewpoint - The article discusses the ongoing controversy surrounding the cosmetic brand "可复美" (Kefumei) and its alleged failure to include recombinant collagen in its products, as raised by a social media influencer known as "大嘴博士" (Dr. Big Mouth) [1][10]. Group 1: Company Responses - 华熙生物 (Hua Xi Biological) expressed strong support for Dr. 郝宇 (Hao Yu) and his company, 上海柳页医创医疗科技服务有限公司, emphasizing the importance of consumer rights and product integrity [3]. - The company has conducted thorough evaluations and tests on the materials provided by Dr. 郝宇 and has received third-party testing results, indicating a commitment to transparency and accountability in the industry [3]. - 华熙生物 called for industry participants and social entities to engage in cross-verification of testing results and urged testing institutions to fulfill their professional responsibilities [3]. Group 2: Controversy and Clarifications - 巨子生物 (Giant Biological) issued a statement acknowledging an apology from the testing institution used by Dr. 郝宇, which clarified that the report was not authorized for public use and was intended solely for research and internal quality control [6][8]. - The testing institution emphasized that the results of the report are not legally binding and are subject to various factors, including sample authenticity and testing conditions, thus limiting their reliability [8]. - 巨子生物 firmly denied allegations of product falsification and asserted that all products comply with regulatory standards, ensuring quality and safety through rigorous verification processes [15].

6月1日，巨子生物发布声明，表示接受"大嘴博士"（郝宇）所用检测机构道歉，但将追究造谣者法律责任。 声明介绍，有关"可复美"未添加重组胶原蛋白的争议，5月30日我司收到了来自"大嘴博士"（郝宇）所用检测机构的道 歉声明，该机构明确表示"我司对此做法不仅不予认同，更从未做出任何形式的授权"，并严令要求"大嘴博士"（郝 宇）"⽴即停⽌使⽤及转发该《测试报告》的⾏为，以避免对社会公众产⽣更严重的误导 "。 根据上海东谱检测技术服务有限公司的声明，近期，名为"大嘴博士"的网络博主在各大网络平台，针对"可复美"品牌 某款化妆品中"重组胶原蛋白"的成分含量提出质疑，并发布相关视频及博文，其中可能引用了我司出具的《测试报 告》作为依据，此举引发了广泛争议。针对该《测试报告》相关情况，我司特作如下澄清说明: 1.报告用途与授权说明:我司出具的该《测试报告》，其明确用途限定为科研、教学以及内部质量控制与研究的目的， 并不具备对社会公众进行证明的法律效力。在受托进行测试时，委托人并未向我司告知其真实用途是为利用该《测试 报告》向社会公众宣传并证明博主观点。我司对此做法不仅不予认同，更从未作出任何形式的授权。 2.测试结果的科学性 ...

HPLC氨基酸法、双缩脲法等不同的检测方法都存在一定的优缺点。 例如HPLC氨基酸法虽然具备高灵敏度等优势，但样品制备过程繁琐，对操作人员的要求较高；双缩脲 法操作简便、快速，但灵敏度低，可能会影响准确性。 重组胶原蛋白龙头企业巨子生物（2367.HK）正卷入成分添加"缺斤短两"的争议中。 5月24日，美妆行业KOL"大嘴博士"（郝宇）发文称通过HPLC高效液相色谱氨基酸定量法（下称"HPLC 氨基酸法"）检测可复美Human-Like重组胶原蛋白肌御修护次抛精华，却发现重组胶原蛋白含量仅为 0.0177%。 可复美正是巨子生物旗下核心品牌之一。 对此，巨子生物亦发文称已对相关产品进行检测，检测结果显示胶原蛋白含量均大于0.1%，与网传 的"0.0177%添加量"严重不符，但其他第三方的检测结果尚未出炉。 争议仍在持续发酵，目前郝宇还提出了巨子生物检测方式的质疑。 5月27日，郝宇发布视频指出，巨子生物申请平台协助删除其质疑视频的文件中，证明了其采用"双缩脲 法"检测胶原蛋白成分含量，但可复美相关产品中含有"聚谷氨酸钠"，双缩脲法会将该物质一同检出， 导致检测结果虚高。 对于郝宇的再度发声，巨子生物内部人士向 ...

近日，一条"巨子生物疑似造假：重组胶原竟然测不到胶原！"的视频及图文网帖，引爆讨论。 其中，检测方法对于成分含量影响的争议，双方各执一词。 可复美送检方法被公开？ 最新的进展是，该博主在5月27日晚，公开了一份自称为"巨子生物向各大平台的举报材料"。 据显示，上述材料名为"关于申请协调删除恶意诋毁诽谤内容的函"。 其中提到巨子生物采用《中华人民共和国药典》2020版四部通则0731第三法及中华人民共和国医药行业 标准YY/T1947-2025《重组胶原蛋白敷料》中重组胶原蛋白含量的检测方法《双缩脲法》，对涉事产品 可复美重组胶原蛋白肌御修护次抛精华液进行含量检测。 1.0版本产品疑"下架" 21世纪经济报道记者查阅多篇知网文献发现，双缩脲法在蛋白质检测中仍有争议。 2008年《河北化工》刊文《蛋白质含量测定方法的比较》中提到，双缩脲法中样品的取用量对测定结果 的准确性有显著影响。双缩脲法可快速测定蛋白质含量，试剂单一，方法简便，但灵敏度差，测定范围 为 1～20 mg 蛋白质。适用于需要快速,但并不需要十分精确的蛋白质测定。 2019年，来自广东医科大学药学院、广东省医疗器械质量监督检验所的六位行业人士撰文中 ...